Upstream Bio Inc (UPB) financials
Upstream Bio revenue and earnings by year
Upstream Bio's revenue was $2.85 million in the fiscal year to December 31, 2025, up 20.4% from the year before. Net income was -$143 million, -5026.0% of revenue. Since the fiscal year to December 31, 2022, revenue has grown 33.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 3 | 2 | 2 | 1 |
| Revenue growth | 20.4% | -0.4% | 96.4% | — |
| Operating income | -160 | -78 | -40 | -24 |
| Operating margin | -5618.8% | -3281.2% | -1685.5% | -1972.7% |
| Net income | -143 | -63 | -21 | -24 |
| Net margin | -5026.0% | -2650.0% | -862.9% | -1969.3% |
| Diluted EPS | -$2.66 | -$5.58 | — | — |
| Free cash flow | -133 | -60 | -38 | -19 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open UPB in Markets.
See also: UPB returns
No forecast, no recommendation. This page describes Upstream Bio Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.